Abbvie Inc (ABBV) |
|
107.985 -0.705 (-0.65%)
|
02-25 11:57 |
|
Open: |
108.48 |
Pre. Close: |
108.69 |
|
High:
|
109.22 |
Low:
|
107.76 |
|
Volume:
|
1,956,311 |
Market Cap:
|
190,689M |
|
|
|
|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
109.535 - 110.307 |
110.307 - 110.906 |
|
Low:
|
104.174 - 104.983 |
104.983 - 105.611 |
|
Close:
|
107.622 - 108.888 |
108.888 - 109.871 |
|
Technical analysis |
as of: 2021-02-25 11:41:25 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 131.69  One year: 153.82 |
| Support: |
Support1: 105.99 Support2: 101.81 |
| Resistance: |
Resistance1: 112.75 Resistance2: 131.69 |
| Pivot: |
106.23  |
| Moving Average: |
MA(5): 107.04 MA(20): 105.65
MA(100): 100.30 MA(250): 93.66 |
| MACD: |
MACD(12,26): 0.18 Signal(9): -0.14 |
| Stochastic oscillator: |
%K(14,3): 65.63 %D(3): 59.25 |
| RSI: |
RSI(14): 55.48 |
| 52-week: |
High: 113.41 Low: 62.55 Change(%): 26.2 |
| Average Vol(K): |
3-Month: 733884 10-Days: 600568 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ABBV has closed below upper band by 21.3%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 23 Feb 2021
AbbVie Inc. stock falls Tuesday, underperforms market - MarketWatch
Mon, 22 Feb 2021
AbbVie Inc. stock outperforms market on strong trading day - MarketWatch
Sun, 21 Feb 2021
Is It Too Late to Buy AbbVie Stock? - Motley Fool
Fri, 19 Feb 2021
AbbVie Inc. stock falls Friday, underperforms market - MarketWatch
Thu, 18 Feb 2021
AbbVie Declares Quarterly Dividend - Yahoo Finance
Thu, 11 Feb 2021
AbbVie Inc. stock falls Thursday, underperforms market - MarketWatch
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General |
| Shares Out. (M) |
1,770 |
| Shares Float (M) |
1,740 |
|
% Held by Insiders
|
0.10 |
|
% Held by Institutions
|
70.00 |
|
Shares Short (K)
|
12,590 |
|
Shares Short P. Month (K)
|
13,850 |
Stock Financials |
|
EPS
|
4.570 |
|
EPS Est This Year
|
5.530 |
|
EPS Est Next Year
|
6.560 |
|
Book Value (p.s.)
|
8.650 |
|
Profit Margin
|
18.16 |
|
Operating Margin
|
33.11 |
|
Return on Assets (ttm)
|
8.1 |
|
Return on Equity (ttm)
|
209.1 |
|
Qtrly Rev. Growth
|
52.2 |
|
Gross Profit (p.s.)
|
14.593 |
|
Sales Per Share
|
22.966 |
|
EBITDA (p.s.)
|
10.379 |
|
Qtrly Earnings Growth
|
22.50 |
|
Operating Cash Flow (M)
|
16,010 |
|
Levered Free Cash Flow (M)
|
13,840 |
Stock Valuations |
|
PE Ratio
|
23.67 |
|
PEG Ratio
|
|
|
Price to Book value
|
12.51 |
|
Price to Sales
|
4.71 |
|
Price to Cash Flow
|
11.96 |
Stock Dividends |
|
Dividend
|
4.720 |
|
Forward Dividend
|
5.200 |
|
Dividend Yield
|
0.04 |
|
Dividend Pay Date
|
2021-02-15 |
|
Ex-Dividend Date
|
2021-01-13 |
|
7 Binary Options
|
|
Your Ad Here
|
|
